MCID: FML125
MIFTS: 17

Familial Hodgkin Disease malady

Categories: Genetic diseases, Immune diseases

Aliases & Classifications for Familial Hodgkin Disease

Aliases & Descriptions for Familial Hodgkin Disease:

Name: Familial Hodgkin Disease 24
Hodgkin's Lymphoma, Familial 24
Hodgkin's Disease, Familial 24
Hodgkin Lymphoma, Familial 24
Familial Hodgkin Lymphoma 24
Hodgkin Disease, Familial 24

Classifications:



Summaries for Familial Hodgkin Disease

MalaCards based summary : Familial Hodgkin Disease, also known as hodgkin's lymphoma, familial, is related to lymphoma, non-hodgkin and hodgkin lymphoma. An important gene associated with Familial Hodgkin Disease is COLQ (Collagen Like Tail Subunit Of Asymmetric Acetylcholinesterase). The drugs Cyclosporine and Cyclophosphamide have been mentioned in the context of this disorder.

Related Diseases for Familial Hodgkin Disease

Diseases related to Familial Hodgkin Disease via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 lymphoma, non-hodgkin 11.0
2 hodgkin lymphoma 9.7
3 chronic lymphocytic leukemia 9.6
4 membranoproliferative glomerulonephritis 9.6
5 nodular lymphocyte predominant hodgkin lymphoma 9.6

Graphical network of the top 20 diseases related to Familial Hodgkin Disease:



Diseases related to Familial Hodgkin Disease

Symptoms & Phenotypes for Familial Hodgkin Disease

Drugs & Therapeutics for Familial Hodgkin Disease

Drugs for Familial Hodgkin Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclosporine Approved, Investigational, Vet_approved Phase 3,Phase 2 79217-60-0, 59865-13-3 5284373 6435893
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
3
Mycophenolic acid Approved Phase 3,Phase 2 24280-93-1 446541
4
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2 128794-94-5 5281078
5
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
6
Tacrolimus Approved, Investigational Phase 3,Phase 1,Phase 2 104987-11-3 445643 439492
7
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
8
Mechlorethamine Approved Phase 3,Phase 2 51-75-2 4033
9
Benzocaine Approved Phase 3,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
10
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
11
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
12
Vinblastine Approved Phase 3,Phase 2 865-21-4 13342 241903
13
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
14
Bleomycin Approved Phase 3,Phase 2 11056-06-7 5360373
15
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
16 tannic acid Approved, Nutraceutical Phase 3,Phase 1,Phase 2
17
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
18
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
19 Alkylating Agents Phase 3,Phase 2,Phase 1
20 Dermatologic Agents Phase 3,Phase 2
21 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
22 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
23 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
24 Antirheumatic Agents Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
26 glucocorticoids Phase 3,Phase 1,Phase 2
27 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
28 Hormone Antagonists Phase 3,Phase 1,Phase 2
29 Hormones Phase 3,Phase 1,Phase 2
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2
31 Etoposide phosphate Phase 3,Phase 2,Phase 1
32 Anti-Inflammatory Agents Phase 3,Phase 1,Phase 2
33 Antineoplastic Agents, Hormonal Phase 3,Phase 1,Phase 2
34 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
35 Podophyllotoxin Phase 3,Phase 2 518-28-5
36 Nitrogen Mustard Compounds Phase 3,Phase 2
37 Keratolytic Agents Phase 3,Phase 2
38 Antimitotic Agents Phase 3,Phase 2,Phase 1
39
Imidazole Phase 3 288-32-4 795
40
Melphalan Approved Phase 2,Phase 1 148-82-3 4053 460612
41
Acetaminophen Approved Phase 2 103-90-2 1983
42
Busulfan Approved, Investigational Phase 2,Phase 1 55-98-1 2478
43
Prednisolone Approved, Vet_approved Phase 2,Phase 1 50-24-8 5755
44
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
45
Diphenhydramine Approved Phase 2 58-73-1, 147-24-0 3100
46
Promethazine Approved Phase 2 60-87-7 4927
47
Methylprednisolone Approved, Vet_approved Phase 2,Phase 1 83-43-2 6741
48
Vidarabine Approved Phase 1, Phase 2 24356-66-9 32326 21704
49
rituximab Approved Phase 2 174722-31-7 10201696
50
Mesna Approved Phase 2 3375-50-6 598

Interventional clinical trials:

(show all 46)
id Name Status NCT ID Phase
1 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
2 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
3 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
4 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
5 Double Cord Versus Haploidentical (BMT CTN 1101) Recruiting NCT01597778 Phase 3
6 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Active, not recruiting NCT00003389 Phase 3
7 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2
8 Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies Unknown status NCT01745913 Phase 2
9 Autologous and Allogeneic Transplant for Relapsed Lymphoma Completed NCT00802113 Phase 1, Phase 2
10 Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma Completed NCT00359892 Phase 2
11 Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies Completed NCT00145613 Phase 2
12 Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies Completed NCT00143559 Phase 2
13 Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases Completed NCT00056966 Phase 1, Phase 2
14 Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer Completed NCT00806767 Phase 2
15 Study of @neWorld: A Virtual Community for Children With Cancer Completed NCT00070421 Phase 1, Phase 2
16 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma Completed NCT00002941 Phase 2
17 Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors Completed NCT00618969 Phase 2
18 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Recruiting NCT01008462 Phase 2
19 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2
20 MSC and HSC Coinfusion in Mismatched Minitransplants Recruiting NCT01045382 Phase 2
21 CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant Recruiting NCT02061800 Phase 1, Phase 2
22 Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies Active, not recruiting NCT00566696 Phase 2
23 S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Active, not recruiting NCT00822120 Phase 2
24 A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor Active, not recruiting NCT01696461 Phase 2
25 Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma Terminated NCT01390584 Phase 2
26 Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant Completed NCT00569283 Phase 1
27 Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer Completed NCT00304018 Phase 1
28 SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma Completed NCT00293488 Phase 1
29 Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer Completed NCT00005785 Phase 1
30 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1
31 Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Recruiting NCT01822509 Phase 1
32 Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia Terminated NCT00933985 Phase 1
33 Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors Terminated NCT00112619 Phase 1
34 Whole-Body MRI and Conventional Imaging in Detecting Distant Metastases in Young Patients With Solid Tumors or Lymphoma Unknown status NCT00072488
35 Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease Completed NCT00521430
36 Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma Completed NCT00981097
37 Genetic Study of Families With High Frequency of Hodgkin Lymphoma Recruiting NCT02795013
38 Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders Recruiting NCT00582621
39 Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies Recruiting NCT00131014
40 Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer Recruiting NCT00039676
41 Familial Investigations of Childhood Cancer Predisposition Recruiting NCT03050268
42 Study of Lymphoma in Asia Recruiting NCT01584141
43 Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment Recruiting NCT01790152
44 Collecting and Storing Tissue From Young Patients With Cancer Recruiting NCT00898755
45 Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer Terminated NCT00301860
46 Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer Terminated NCT01744821

Search NIH Clinical Center for Familial Hodgkin Disease

Genetic Tests for Familial Hodgkin Disease

Genetic tests related to Familial Hodgkin Disease:

id Genetic test Affiliating Genes
1 Familial Hodgkin Disease 24

Anatomical Context for Familial Hodgkin Disease

Publications for Familial Hodgkin Disease

Articles related to Familial Hodgkin Disease:

id Title Authors Year
1
HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease. ( 11781255 )
2002
2
Letter: Familial Hodgkin disease. ( 4479174 )
1974

Variations for Familial Hodgkin Disease

Expression for Familial Hodgkin Disease

Search GEO for disease gene expression data for Familial Hodgkin Disease.

Pathways for Familial Hodgkin Disease

GO Terms for Familial Hodgkin Disease

Sources for Familial Hodgkin Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....